Ghana's Green Pharmacy: Unlocking the Healing Power of Our Plants, Safely

Yakubu Adam, Toxicologist

Walk through any Ghanaian market, from Kumasi's Kejetia to Makola in Accra to Tamale Central, and you will see it: bundles of roots, barks, leaves and seeds, sold by people who learned their use from parents and grandparents. For generations, these plants have treated fevers, wounds, stomach ailments, coughs and more. We often treat this as culture or folklore. Science should treat it as something else: an unmined library of chemistry.

Africa is home to roughly a quarter of the world's plant biodiversity, and Ghana, with its forest belt, savannah, coastal and montane ecosystems, holds a generous share of it. The World Health Organization has long estimated that a large majority of people in many African countries rely on traditional medicine for some of their primary health care. That is not a footnote to our health system. In practice, it is a major part of our health system.

The world has already shown what happens when this chemistry is studied seriously. Artemisinin, the backbone of modern malaria treatment, came from sweet wormwood, a plant used in Chinese traditional medicine, and earned a Nobel Prize in 2015. Vincristine and vinblastine, important cancer medicines, were derived from the Madagascar periwinkle. Morphine came from the opium poppy. Quinine came from the bark of the cinchona tree. A very large share of modern drugs trace back, directly or indirectly, to natural products.

The question for Ghana is simple: if others built medicines from the world's plants, what are we building from ours?

Ghana already has the proof of concept

We are not starting from zero. Ghanaian scientists have studied Cryptolepis sanguinolenta, known locally as nibima, for its antimalarial activity. Research institutions such as the Centre for Plant Medicine Research at Mampong-Akuapem, the Kwame Nkrumah University of Science and Technology (KNUST), the University of Ghana and the University of Cape Coast have produced valuable work on medicinal plants. Ghana also has a Herbal Pharmacopoeia and the Traditional Medicine Practice Act, and the Food and Drugs Authority (FDA) registers herbal medicinal products.

The foundations exist. What is missing is scale, funding and follow-through. Too many promising findings end as a journal article or a thesis on a library shelf, never progressing to standardised extracts, safety studies, clinical trials or products on a pharmacy shelf.

The hidden treasure of orphan receptors

Here is a frontier that most of the public has never heard about, and one where our plants may matter enormously.

Your body is full of receptors, protein switches on the surface of cells that respond to chemical signals and control everything from heartbeat to mood to blood sugar. Many of today's medicines work by acting on them. Yet scientists have identified a substantial number of receptors, particularly in the large G protein-coupled receptor (GPCR) family, for which the natural molecule that switches them on, the endogenous ligand, is still unknown. These are called orphan receptors.

Why does this matter? Because every time an orphan receptor has been "adopted", that is, matched with its ligand, the result has often been a new therapeutic target. The discovery of the orexin system, for example, opened the door to a new class of insomnia medicines. The story of the opioid and cannabinoid systems is even more instructive: plants came first. Morphine from the poppy and THC from cannabis pointed scientists to receptors in our own bodies, and from there to the body's own opioid and endocannabinoid signalling molecules.

The lesson is powerful. Plant chemicals are not only potential drugs; they are also probes. They can reveal receptors, pathways and biology we did not know existed. Ghanaian and African plants, shaped by millions of years of evolution under intense ecological pressure, produce an enormous variety of compounds. Screening well-characterised extracts and isolated compounds against orphan receptors is a legitimate and promising research strategy. Finding ligands for even a few of these receptors could open new treatment routes for metabolic, neurological, inflammatory, cardiovascular and cancer-related conditions.

We should be honest: this is hard, expensive science. It needs modern equipment, trained people and sustained funding. But it is precisely the kind of science in which a country with rich biodiversity and a growing base of researchers can compete, if it chooses to invest.

Orphan diseases and neglected conditions

There is a second kind of orphan: the disease that attracts little pharmaceutical investment because the patient population is small or too poor to promise returns. Rare genetic disorders and neglected tropical diseases fall in this category. In Ghana, conditions such as Buruli ulcer, lymphatic filariasis, onchocerciasis and sickle cell disease affect real families, often in communities far from the spotlight.

Commercial drug developers will not always rush to solve these problems. A country that wants answers must be willing to fund its own research. Natural product research, built on local knowledge and local biodiversity, is one of the most cost-effective ways to begin.

Why government must put money where the potential is

Speeches about the value of traditional medicine are plentiful. Budget lines are not. If Ghana is serious about integrating herbal medicine with orthodox care, government must commit dedicated, protected, multi-year funding. Here is what that should look like:

1. A national natural product research fund, ring-fenced and competitively awarded to universities, research institutes and collaborative teams, with clear milestones from plant collection to clinical evaluation.
2. Modern laboratory infrastructure: analytical chemistry, high-throughput screening, toxicology and quality control facilities that can generate data accepted by international regulators.
3. Proper documentation and protection of indigenous knowledge, with benefit-sharing arrangements so that traditional healers and communities are credited and rewarded, not exploited. Ghana's obligations under the Nagoya Protocol on access and benefit-sharing should guide this.
4. Clinical trial capacity for herbal products, so that claims are tested the same way any other medicine is tested.
5. Cultivation and conservation programmes. Medicinal plants cannot be wild-harvested into extinction. Many species are threatened by deforestation and illegal mining. Sustainable farming of priority species protects both biodiversity and incomes, and gives us consistent raw material.
6. Genuine integration: structured collaboration, referral pathways and training that bring licensed herbal practitioners and orthodox clinicians into the same conversation, with the patient's safety at the centre.

This is not charity to tradition. It is investment in health security, local industry, jobs for farmers and processors, and national pride. Countries that have developed their traditional medicine sectors, such as China and India, have turned them into both health resources and economic engines.

"Natural" does not mean "safe"

Now, a necessary warning, and it is one I give as a toxicologist.

Somewhere along the way, many people absorbed a dangerous idea: if it comes from a plant, it cannot harm you. Nature produces some of the most potent poisons on earth. Cyanide-releasing compounds, toxic alkaloids, and fungal toxins are all natural. Penicillin and strychnine are both natural too, and one saves lives while the other kills.

Herbal products can cause harm in several ways:

• Inherent toxicity of the plant. Some plants contain compounds that damage the liver, kidneys, heart or nervous system. Certain pyrrolizidine alkaloids, for example, are known liver toxins, and aristolochic acid, found in some Aristolochia species, has been linked to kidney failure and cancer.
• Wrong dose. Many preparations have no standard dose. "A handful", "a cup", "until you feel better" is not dosing. The difference between a therapeutic and a toxic amount can be narrow.
• Contamination. Herbal products may carry heavy metals such as lead, mercury and arsenic, pesticide residues, and moulds that produce aflatoxins. Where plants are harvested near polluted water or mining sites, the risk is real.
• Adulteration. Some products are secretly spiked with pharmaceutical drugs such as steroids or painkillers, or with substances that are simply not on the label. The patient thinks they are taking a herb, and they are not.
• Herb-drug interactions. Herbs can change how conventional medicines are absorbed or broken down. St John's wort, for example, is known to reduce the effectiveness of several medicines, including some antiretrovirals and anticoagulants. A person on treatment for hypertension, diabetes, HIV or epilepsy who adds an unregulated herbal remedy may undermine their care without knowing it.
• Delay in proper treatment. Perhaps the most common harm of all: a patient with a treatable condition spends weeks on a herbal remedy while the disease advances.
• Abuse. Mixing, doubling and overusing products because "herbal cannot harm" is a recipe for kidney and liver injury, which is often silent until it is severe.

In Ghana, products are advertised on radio, television, social media and roadside vans with sweeping claims to cure diabetes, hypertension, infertility, cancer and sometimes several conditions at once. Many of these claims have never been tested. Customers are rarely told about side effects, contraindications or the right dose. This is not respect for traditional medicine; it is exploitation of it.

Regulation is not the enemy of herbal medicine; it is its protector

Good regulation separates the genuine from the fraudulent. It protects patients, and it protects honest practitioners and manufacturers from being tarred by quacks. Ghana's regulatory framework, anchored by the FDA and the Traditional Medicine Practice Council, is a good start. It now needs strengthening in several areas:

• Enforcement: unregistered products and unapproved health claims must carry real consequences, including in broadcast and online advertising.
• Quality standards: mandatory testing for heavy metals, microbial contamination, aflatoxins and pesticide residues, and standardisation of active or marker compounds.
• Labelling: clear ingredients, dosage, duration of use, warnings and batch numbers on every product.
• Pharmacovigilance: a working system to collect and act on reports of adverse reactions to herbal medicines, just as we do for conventional drugs. Healthcare workers and the public should know how to report.
• Practitioner standards: training, licensing and continuing education for herbal practitioners.
• Evidence-based claims: products that claim to treat serious diseases should be required to show supporting evidence.

A well-regulated herbal sector is a cornerstone of what we might call health sovereignty: the ability of Ghana to meet more of its own health needs with its own knowledge, its own resources and its own quality-assured products, rather than depending wholly on imported medicines and external priorities.

What the toxicologist can do

This is where I turn the lens on my own profession. Toxicologists must not stand at the side and merely warn. We are central to making herbal medicine both usable and safe. In my view, here is how toxicologists in Ghana can contribute:

1. Generate the safety data. Acute, sub-chronic and chronic toxicity studies, genotoxicity and organ-specific assessments of commonly used Ghanaian medicinal plants and products. A herbal medicine without safety data is an experiment on the public.
2. Define safe dose ranges. Move from "a handful" to evidence-based, standardised dosing with clear upper limits and duration of use.
3. Support quality control. Work with the FDA, Ghana Standards Authority and universities to develop testing protocols for contaminants and adulterants, and to build laboratory capacity for routine screening.
4. Build a national herbal toxicity database, drawing on poison centre cases, hospital records, forensic casework and published studies, so that clinicians and regulators can see which products and plants are causing harm.
5. Strengthen clinical toxicology and pharmacovigilance. Train doctors, pharmacists and nurses to ask patients about herbal use, recognise herb-induced injury and report it.
6. Investigate harm properly. In forensic and clinical settings, include herbal products in toxicological analysis when poisoning or unexplained organ failure is suspected.
7. Collaborate with traditional healers, not against them. Respectful engagement, training on safe preparation, hygiene and dosing, and joint research will do more than confrontation.
8. Include toxicology early in drug discovery. For anyone screening plants for new therapeutic leads, including leads against orphan receptors, safety assessment should not be an afterthought. Early toxicology saves time, money and lives.
9. Speak to the public. Use radio, television, social media, schools and community forums to correct myths, especially the idea that "natural" means "harmless". Public education is as powerful as any laboratory.
10. Train the next generation. Support students and young scientists in toxicology, pharmacognosy and drug discovery, and push for these fields to be properly funded in our universities.
11. Advise policy. Provide evidence to Parliament, the Ministry of Health and regulators on what an effective, science-based herbal policy requires.
12. Protect the sources. Environmental toxicology matters too. Contamination of land and water by mining chemicals such as mercury and cyanide threatens the very plants and communities we hope to benefit from.

The road ahead

Ghana's plants are not a relic of the past. They are a resource for the future, but only if we treat them with the seriousness they deserve. That means three commitments held together:

• Invest: fund the science that turns indigenous knowledge into validated, standardised medicines, including the search for ligands of orphan receptors and treatments for neglected diseases.
• Integrate: bring traditional and orthodox practitioners into respectful, evidence-guided partnership.
• Regulate: protect the public from unsafe, unproven and fraudulent products, and protect good herbal medicine from the damage that bad products do to its name.

The forests, savannahs and gardens of Ghana have held medicines for centuries. Our task now is to discover them rigorously, prove them honestly, and use them safely. If we do, we will not only treat disease; we will build health independence for generations.

The treasure is real. Let us have the courage to fund it, the discipline to test it, and the wisdom to regulate it.

Yakubu Adam is a Toxicologist with FIND-GH and a lecturer in public health and toxicology.